CT

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Bio & Pharma SK C&C wins Korea’s nod for brain infarct diagnosis AI solution

SK Inc C&C (SK C&C), the information technology service unit of South Korea’s SK Group, said on Thursday it has secured medical device...

Bio & Pharma Celltrion applies for approval of Xolair biosimilar in Canada

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...

Bio & Pharma Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

Bio & Pharma Celltrion to release Stelara biosimilar in US from March 2025

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the m...

Bio & Pharma Celltrion gets OK partial approval for phase 3 of biosimilar in Europe

South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...

Bio & Pharma Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US

South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...

Bio & Pharma Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe

South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...

Bio & Pharma Celltrion gets FDA approval for Humira biosimilar CT-P17

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

Bio & Pharma Celltrion applies for Phase 3 clinical trials in Europe for biosimilar

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...

Bio & Pharma Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...